北京协和医学院比较医学中心,中国医学科学院医学实验动物研究所,国家卫生健康委员会人类疾病比较医学重点实验室, 国家中医药管理局人类疾病动物模型三级实验室,新发再发传染病动物模型研究北京市重点实验室,北京 100021
R-33
YU Wenhui
Comparative Medicine Center, Peking Union Medical College (PUMC) & Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS); NHC Key Laboratory of Human Disease Comparative Medicine; Key Laboratory of Human Diseases Animal Models; State Administration of Traditional Chinese Medicine; Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Beijing 100021, ChinaYANG Chenbo
Comparative Medicine Center, Peking Union Medical College (PUMC) & Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS); NHC Key Laboratory of Human Disease Comparative Medicine; Key Laboratory of Human Diseases Animal Models; State Administration of Traditional Chinese Medicine; Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Beijing 100021, ChinaCONG Zhe
Comparative Medicine Center, Peking Union Medical College (PUMC) & Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS); NHC Key Laboratory of Human Disease Comparative Medicine; Key Laboratory of Human Diseases Animal Models; State Administration of Traditional Chinese Medicine; Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Beijing 100021, ChinaXUE Jing
Comparative Medicine Center, Peking Union Medical College (PUMC) & Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS); NHC Key Laboratory of Human Disease Comparative Medicine; Key Laboratory of Human Diseases Animal Models; State Administration of Traditional Chinese Medicine; Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Beijing 100021, ChinaComparative Medicine Center, Peking Union Medical College (PUMC) & Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS); NHC Key Laboratory of Human Disease Comparative Medicine; Key Laboratory of Human Diseases Animal Models; State Administration of Traditional Chinese Medicine; Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Beijing 100021, China
目的 研究程序性细胞死亡蛋白 2(programmed cell death protein 2,PDCD2)过表达对 T 淋巴细胞株 Jurkat 及 HIV 潜伏感染 T 细胞株 ACH2 凋亡的影响。 方法 用 T 淋巴细胞株 Jurkat 及 HIV 潜伏感染 T 细胞株 ACH2 作为细胞模型,采用慢病毒转染技术分别在上述细胞株过表达 PDCD2 基因,在未刺激和肿瘤坏死因子相关凋亡诱导配体(tumor necrosis factor (TNF)-related apoptosis-inducing ligand,TRAIL)刺激 24 h 后,经 PE-Annexin V、 7-AAD 检测细胞凋亡的情况。 结果 在无刺激剂的情况下,Jurkat 和 ACH2 细胞的凋亡率并未因细胞内 PDCD2 表达量的增加而改变;在 TRAIL 刺激下,与对照组相比,高表达 PDCD2 基因的 Jurkat 和 ACH2 细胞凋亡率显著增高, 有统计学差异(P<0.05)。 结论 PDCD2 能促进 TRAIL 刺激下 T 细胞及 HIV 潜伏感染 T 细胞的凋亡水平。
Objective To investigate apoptosis after PDCD2 overexpression in Jurkat and ACH2 cell lines. Methods Jurkat and ACH2 cell lines were used in this study. PDCD2 was stably expressed in the cell lines by lentivirus infection. Apoptosis was determined by flow cytometry after 24 hours of TRAIL treatment. Results Apoptosis was not significantly increased in Jurkat or ACH2 cells stably expressing PDCD2 compared with untransfected control cells. However, compared with the control group without PDCD2 overexpression, apoptosis was significantly higher in PDCD2- Jurkat and PDCD2-ACH2 cells induced by TRAIL (P< 0.05). Conclusions PDCD2 promotes apoptosis of T cell and HIV latent-infected T cells induced by TRAIL.
余雯惠,杨晨波,丛喆,薛婧. PDCD2 促进 TRAIL 刺激下 T 细胞及 HIV 潜伏感染 T 细胞的凋亡[J].中国比较医学杂志,2022,32(5):1~6.
复制